NO20071585L - Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte - Google Patents

Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte

Info

Publication number
NO20071585L
NO20071585L NO20071585A NO20071585A NO20071585L NO 20071585 L NO20071585 L NO 20071585L NO 20071585 A NO20071585 A NO 20071585A NO 20071585 A NO20071585 A NO 20071585A NO 20071585 L NO20071585 L NO 20071585L
Authority
NO
Norway
Prior art keywords
pain
treatment
nucleoside
chemotherapy
peptide compounds
Prior art date
Application number
NO20071585A
Other languages
English (en)
Inventor
Thomas Stohr
Bettina Beyreuther
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04020402A external-priority patent/EP1629839A1/en
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of NO20071585L publication Critical patent/NO20071585L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sammendrag Foreliggende oppfinnelse er rettet mot anvendelse av en klasse av peptidforbindelser for behandling av tumorsmerte, fortrinnsvis benkreftsmerte, for behandling av kjemoterapiindusert smerte og for behandling av nukleosidindusert smerte.
NO20071585A 2004-08-27 2007-03-26 Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte NO20071585L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60481004P 2004-08-27 2004-08-27
EP04020402A EP1629839A1 (en) 2004-08-27 2004-08-27 Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
PCT/EP2005/009067 WO2006021412A2 (en) 2004-08-27 2005-08-22 Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain

Publications (1)

Publication Number Publication Date
NO20071585L true NO20071585L (no) 2007-04-30

Family

ID=35456911

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071585A NO20071585L (no) 2004-08-27 2007-03-26 Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte

Country Status (17)

Country Link
US (2) US7687553B2 (no)
EP (1) EP1781276B1 (no)
JP (1) JP2008510758A (no)
KR (1) KR20070045271A (no)
AR (1) AR050612A1 (no)
AT (1) ATE471717T1 (no)
AU (1) AU2005276634B2 (no)
BR (1) BRPI0514721A (no)
CA (1) CA2573125A1 (no)
DE (1) DE602005021970D1 (no)
EA (1) EA014055B1 (no)
IL (1) IL181383A0 (no)
MX (1) MX2007002269A (no)
NO (1) NO20071585L (no)
NZ (1) NZ552651A (no)
PL (1) PL1781276T3 (no)
WO (1) WO2006021412A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633169A1 (de) 1996-08-17 1998-02-19 Teves Gmbh Alfred Elektromotor-/Pumpenaggregat
EP1243262B1 (en) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
EP1243263B1 (en) * 2001-03-21 2002-11-27 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
AU2004294714B2 (en) * 2003-12-02 2009-12-10 Ucb Pharma Gmbh Novel use of peptide compounds for treating central neuropathic pain
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
MXPA06011937A (es) 2004-04-16 2007-01-26 Sanol Arznei Schwarz Gmbh Uso de compuestos peptidicos para la profilaxis y el tratamiento de dolor de cabeza cronico.
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
BRPI0514721A (pt) * 2004-08-27 2008-06-24 Sanol Arznei Schwarz Gmbh uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
SI2462990T1 (sl) * 2006-06-15 2014-04-30 Ucb Pharma Gmbh Farmacevtski sestavek, ki obsega lakozamid in levetiracetam, s sinergističnim antikonvulzivnim učinkom
CA2774569A1 (en) 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
NZ610701A (en) 2010-12-02 2015-06-26 Ucb Pharma Gmbh Once daily formulation of lacosamide
US9134395B2 (en) 2012-03-07 2015-09-15 Freescale Semiconductor, Inc. Method for testing comparator and device therefor
WO2017119022A1 (ja) * 2016-01-07 2017-07-13 パナソニックＩｐマネジメント株式会社 発光装置

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) * 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (no) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) * 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
EP0784629B1 (en) * 1994-10-05 1999-04-28 Darwin Discovery Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
JP4313435B2 (ja) * 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
US6114390A (en) * 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5773455A (en) * 1996-06-28 1998-06-30 Biomeasure, Incorporated Inhibitors of prenyl transferases
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
PL189872B1 (pl) * 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
AU7937298A (en) 1997-07-08 1999-02-08 Ono Pharmaceutical Co. Ltd. Amino acid derivatives
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO1999007413A1 (en) 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
US6509341B1 (en) 1997-10-31 2003-01-21 Abbott Laboratories Carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
CA2361402C (en) 1999-09-03 2009-05-12 Actelion Pharmaceuticals Ltd Bis-sulfonamides
SE0001373D0 (sv) 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
AU8830801A (en) 2000-08-17 2002-02-25 Teva Pharma Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
DE60142806D1 (de) 2000-08-25 2010-09-23 Res Corp Technologies Inc Aminosäure enthaltende Antikonvulsiva zur Behandlung von Zwangsstörungen
AU2002224847A1 (en) 2000-11-21 2002-06-03 U C B, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
EP1243262B1 (en) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
EP1243263B1 (en) * 2001-03-21 2002-11-27 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
KR20040016844A (ko) 2001-03-27 2004-02-25 액테리온 파마슈티칼 리미티드 유로텐신 ⅱ 수용체 길항제인1,2,3,4-테트라하이드로이소퀴놀린 유도체
MXPA03009689A (es) 2001-04-26 2004-02-12 Bristol Myers Squibb Co TABLETA FARMACEUTICA QUE TIENE ALTO CONTENIDO DE INGREDIENTE FARMACeUTICO ACTIVO (IFA).
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
PT1546134E (pt) 2002-08-05 2007-08-10 Lilly Co Eli ''arilbenzodiazepinas substituídas com piperazina''
KR20050074571A (ko) 2002-11-11 2005-07-18 바이엘 헬스케어 아게 Ｉｐ 수용체 길항제로서의 페닐 또는 헤테로아릴 아미노알칸 유도체
EP1601691B1 (en) 2002-11-18 2008-01-16 BioProspecting NB Inc. Shrew paralytic peptide for use in neuromuscular therapy
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
ES2280835T3 (es) 2002-12-19 2007-09-16 Pharmacia Corporation Formulacion no higroscopica que comprende un farmaco higroscopico.
WO2004066987A2 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
WO2004066990A2 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040266743A1 (en) 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7320675B2 (en) * 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
EP1537862A1 (en) 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
AU2004294714B2 (en) * 2003-12-02 2009-12-10 Ucb Pharma Gmbh Novel use of peptide compounds for treating central neuropathic pain
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1541138A1 (en) 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
MXPA06011937A (es) * 2004-04-16 2007-01-26 Sanol Arznei Schwarz Gmbh Uso de compuestos peptidicos para la profilaxis y el tratamiento de dolor de cabeza cronico.
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
BRPI0514721A (pt) 2004-08-27 2008-06-24 Sanol Arznei Schwarz Gmbh uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP1688137A1 (en) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 for add-on therapy of schizophrenia
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
SI2462990T1 (sl) * 2006-06-15 2014-04-30 Ucb Pharma Gmbh Farmacevtski sestavek, ki obsega lakozamid in levetiracetam, s sinergističnim antikonvulzivnim učinkom
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP2214657A1 (en) * 2007-10-23 2010-08-11 UCB Pharma GmbH Compounds for treating demyelination conditions

Also Published As

Publication number Publication date
US7687553B2 (en) 2010-03-30
AU2005276634A1 (en) 2006-03-02
CA2573125A1 (en) 2006-03-02
DE602005021970D1 (de) 2010-08-05
WO2006021412A2 (en) 2006-03-02
MX2007002269A (es) 2007-06-15
WO2006021412A3 (en) 2006-04-27
US8536137B2 (en) 2013-09-17
AR050612A1 (es) 2006-11-08
BRPI0514721A (pt) 2008-06-24
JP2008510758A (ja) 2008-04-10
EP1781276B1 (en) 2010-06-23
US20100029543A1 (en) 2010-02-04
IL181383A0 (en) 2008-03-20
KR20070045271A (ko) 2007-05-02
EA200700493A1 (ru) 2007-08-31
AU2005276634B2 (en) 2011-03-24
EP1781276A2 (en) 2007-05-09
EA014055B1 (ru) 2010-08-30
ATE471717T1 (de) 2010-07-15
NZ552651A (en) 2010-07-30
US20060046957A1 (en) 2006-03-02
PL1781276T3 (pl) 2010-11-30

Similar Documents

Publication Publication Date Title
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
DE50310516D1 (de) Fredericamycin-derivate
CY1109229T1 (el) Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
TNSN05300A1 (en) Treatment with anti-vegf antibodies
NO20054494L (no) Peptidvektorer
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
IS6891A (is) Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins
GB0121490D0 (en) Ciompounds
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
UY27812A1 (es) Uso de docetasel-doxorubin-ciclofosfamida como apoyo de terapias
EA201400423A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
EA200801425A1 (ru) Диазепиноны
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
GB0121494D0 (en) Compounds
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling
HUP0301276A2 (hu) Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
TW200616659A (en) Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-included pain
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application